SIBP-03 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SIBP-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SIBP-03 overview
SIBP-03 is under development for the treatment of advanced malignant solid tumors including recurrent head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma (ESCC) and breast cancer with high HER2 expression. The drug candidate is a recombinant monoclonal antibody administered through intravenous route. It acts by targeting tyrosine kinase type cell surface receptor (HER3).
Shanghai Institute of Biological Products overview
Shanghai Institute of Biological Products (SIBP) engaged in production and distribution of bacterial and virus vaccines, toxoids, and analogous products. It serves various markets including medical clinics and hospitals, pharmaceuticals, health information systems, dental and orthodontic practitioners. The company is headquartered in Shanghai, China.
For a complete picture of SIBP-03’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
